{"id":3738,"date":"2020-10-01T11:28:16","date_gmt":"2020-10-01T10:28:16","guid":{"rendered":"https:\/\/www.ab-science.com\/sclerose-en-plaques\/"},"modified":"2025-05-21T14:11:46","modified_gmt":"2025-05-21T13:11:46","slug":"sclerose-en-plaques","status":"publish","type":"page","link":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-en-plaques\/","title":{"rendered":"Scl\u00e9rose en plaques"},"content":{"rendered":"

[vc_row][vc_column]

<\/span>\u00c0 propos de la scl\u00e9rose en plaques<\/span><\/div><\/div>
<\/div>[vc_column_text]La scl\u00e9rose en plaques (SEP) est une maladie du syst\u00e8me nerveux central (SNC) caract\u00e9ris\u00e9e par une d\u00e9gradation progressive des cellules nerveuses du SNC par le syst\u00e8me immunitaire du patient et se pr\u00e9sente sous deux formes principales : la forme r\u00e9currente-r\u00e9mittente caract\u00e9ris\u00e9e par des rechutes de la maladie et la forme progressive, caract\u00e9ris\u00e9e par une aggravation constante et r\u00e9guli\u00e8re des sympt\u00f4mes de la maladie, sans rechute distincte ni p\u00e9riode de r\u00e9cup\u00e9ration.<\/p>\n

Bien que des progr\u00e8s significatifs aient \u00e9t\u00e9 r\u00e9alis\u00e9s dans la forme r\u00e9currente de la SEP, avec plus de 15 m\u00e9dicaments approuv\u00e9s, il existe toujours un tr\u00e8s fort besoin m\u00e9dical non satisfait pour traiter les patients atteints de SEP progressive primaire et de SEP secondairement progressive non active, aucun m\u00e9dicament n\u2019\u00e9tant approuv\u00e9 pour la SEP secondairement progressive non active et un seul pour la SEP progressive primaire.[\/vc_column_text]

<\/span>Positionnement du masitinib dans la scl\u00e9rose en plaques<\/span><\/div><\/div>
<\/div>[vc_column_text]Dans la scl\u00e9rose en plaques progressive, il a \u00e9t\u00e9 d\u00e9montr\u00e9 que les cellules immunitaires inn\u00e9es telles que les macrophages, les microglies ou les mastocytes jouent probablement un r\u00f4le majeur. Le masitinib est con\u00e7u pour les formes progressives de la scl\u00e9rose en plaques, en ciblant le syst\u00e8me immunitaire inn\u00e9, en particulier les mastocytes et les microglies.[\/vc_column_text]
<\/div>
<\/span>R\u00e9sultats positifs de phase 2a du masitinib dans les formes progressives de la scl\u00e9rose en plaques<\/span><\/div><\/div>
<\/div>[vc_column_text]Cette \u00e9tude de phase 2a a montr\u00e9 que pour le crit\u00e8re d\u2019\u00e9valuation principal du MSFC (qui mesure les sympt\u00f4mes des patients sur trois aspects : mouvement des membres inf\u00e9rieurs, mouvement des membres sup\u00e9rieurs et tests cognitifs), 32% des patients trait\u00e9s par le masitinib ont r\u00e9pondu au traitement contre 0% avec le placebo. Une r\u00e9ponse clinique a \u00e9t\u00e9 d\u00e9finie comme une variation sup\u00e9rieure \u00e0 100% rapport \u00e0 la valeur observ\u00e9e \u00e0 l\u2019inclusion dans le score MSFC.<\/p>\n

Les r\u00e9sultats de cette \u00e9tude de phase 2a ont \u00e9t\u00e9 publi\u00e9s<\/a> dans BMC Neurology.[\/vc_column_text]

<\/span>R\u00e9sultats positifs de phase 2B\/3 du masitinib dans les formes progressives de la scl\u00e9rose en plaques<\/span><\/div><\/div>
<\/div>[vc_column_text]AB Science a rapport\u00e9 des r\u00e9sultats positifs de la phase 2B\/3 avec le masitinib dans les formes progressives de la SEP. Dans cette \u00e9tude, le masitinib a ralenti la progression de la maladie chez les patients, ce qui \u00e9tait l’objectif principal de l’\u00e9tude, tel que mesur\u00e9 par le changement sur l’\u00e9chelle EDSS (Expanded Disability Status Scale). Le masitinib a \u00e9galement d\u00e9montr\u00e9 une r\u00e9duction significative du risque d’atteindre un niveau de handicap suffisamment grave pour n\u00e9cessiter une mobilit\u00e9 en fauteuil roulant.[\/vc_column_text][vc_column_text]<\/p>\n

Analyse primaire – Changement dans l’EDSS jusqu’\u00e0 la semaine 96 (une valeur positive indique une aggravation)<\/p>\n

[\/vc_column_text][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/6″][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb2\/3″][vc_single_image image=\u00a0\u00bb892″ img_size=\u00a0\u00bbfull\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb css_animation=\u00a0\u00bbfadeIn\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/6″][\/vc_column_inner][\/vc_row_inner][vc_column_text]Les r\u00e9sultats de l’\u00e9tude ont \u00e9t\u00e9 pr\u00e9sent\u00e9s lors de la 8e<\/sup> r\u00e9union conjointe des Comit\u00e9s Europ\u00e9en (ECTRIMS) et Am\u00e9ricain (ACTRIMS) pour le Traitement et la Recherche sur la Scl\u00e9rose en plaques (MSVirtual2020) et fournit les premi\u00e8res preuves cliniques que le ciblage du syst\u00e8me immunitaire inn\u00e9 est une strat\u00e9gie efficace pour le traitement des formes progressives de la scl\u00e9rose en plaques.[\/vc_column_text]

<\/span>\u00c9tude confirmatoire de Phase 3 avec le masitinib dans le traitement des formes progressives de la scl\u00e9rose en plaques<\/span><\/div><\/div>
<\/div>[vc_column_text]AB Science a re\u00e7u l\u2019autorisation pour initier une \u00e9tude confirmatoire de phase 3 \u00e9valuant le masitinib chez les patients atteints de scl\u00e9rose en plaques progressive primaire (PPMS) ou de scl\u00e9rose en plaques secondairement progressive non-active (nSPMS). L’\u00e9tude doit recruter 800 patients provenant de nombreux centres et pr\u00e9sentant un score EDSS (Expanded Disability Status Scale) compris entre 3,0 et 6,0 et une absence de l\u00e9sions c\u00e9r\u00e9brales T1 rehauss\u00e9es apr\u00e8s injection de gadolinium, mesur\u00e9 par IRM (imagerie par r\u00e9sonance magn\u00e9tique). L’objectif principal de l’\u00e9tude sera d’\u00e9valuer l’effet du masitinib sur le d\u00e9lai avant progression confirm\u00e9e du handicap, la progression \u00e9tant d\u00e9finie comme une aggravation d’un point lorsque le score EDSS \u00e0 l\u2019inclusion est inf\u00e9rieur ou \u00e9gal \u00e0 5,5, ou d\u2019un demi-point lorsque le score EDSS \u00e0 l\u2019inclusion est strictement sup\u00e9rieur \u00e0 5,5, entre la randomisation et la semaine 96.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_column_text]La scl\u00e9rose en plaques (SEP) est une maladie du syst\u00e8me nerveux central (SNC) caract\u00e9ris\u00e9e par une d\u00e9gradation progressive des cellules nerveuses du SNC par le syst\u00e8me immunitaire du patient et se pr\u00e9sente sous deux formes principales : la forme r\u00e9currente-r\u00e9mittente caract\u00e9ris\u00e9e par des rechutes de la maladie et la forme progressive, caract\u00e9ris\u00e9e par une aggravation…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3763,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3738","page","type-page","status-publish","hentry","description-off"],"yoast_head":"\nScl\u00e9rose en plaques – AB Science<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-en-plaques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Scl\u00e9rose en plaques\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text]La scl\u00e9rose en plaques (SEP) est une maladie du syst\u00e8me nerveux central (SNC) caract\u00e9ris\u00e9e par une d\u00e9gradation progressive des cellules nerveuses du SNC par le syst\u00e8me immunitaire du patient et se pr\u00e9sente sous deux formes principales : la forme r\u00e9currente-r\u00e9mittente caract\u00e9ris\u00e9e par des rechutes de la maladie et la forme progressive, caract\u00e9ris\u00e9e par une aggravation…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-en-plaques\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T13:11:46+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/sclerose-en-plaques\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/sclerose-en-plaques\\\/\",\"name\":\"Scl\u00e9rose en plaques – AB Science\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-10-01T10:28:16+00:00\",\"dateModified\":\"2025-05-21T13:11:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/sclerose-en-plaques\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/sclerose-en-plaques\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/sclerose-en-plaques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Masitinib\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-overview\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Scl\u00e9rose en plaques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Scl\u00e9rose en plaques – AB Science","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-en-plaques\/","og_locale":"fr_FR","og_type":"article","og_title":"Scl\u00e9rose en plaques","og_description":"[vc_row][vc_column][vc_column_text]La scl\u00e9rose en plaques (SEP) est une maladie du syst\u00e8me nerveux central (SNC) caract\u00e9ris\u00e9e par une d\u00e9gradation progressive des cellules nerveuses du SNC par le syst\u00e8me immunitaire du patient et se pr\u00e9sente sous deux formes principales : la forme r\u00e9currente-r\u00e9mittente caract\u00e9ris\u00e9e par des rechutes de la maladie et la forme progressive, caract\u00e9ris\u00e9e par une aggravation…","og_url":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-en-plaques\/","og_site_name":"AB Science","article_modified_time":"2025-05-21T13:11:46+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-en-plaques\/","url":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-en-plaques\/","name":"Scl\u00e9rose en plaques – AB Science","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2020-10-01T10:28:16+00:00","dateModified":"2025-05-21T13:11:46+00:00","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-en-plaques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-en-plaques\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-en-plaques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Pipeline","item":"https:\/\/www.ab-science.com\/fr\/pipeline\/"},{"@type":"ListItem","position":3,"name":"Masitinib","item":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-overview\/"},{"@type":"ListItem","position":4,"name":"Scl\u00e9rose en plaques"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=3738"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3738\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3763"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=3738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}